RxDoctor Payments Data

Warren Stribling, MD

Advanced Heart Failure and Transplant Cardiology · Nashville, TNNPI 1720241185

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $16,430 of the $23,245 with a category attached, or 70.7%. Novartis accounts for 77.5% of it on its own, with 20 other manufacturers making up the rest. Reporting peaked in 2019 at $18,470 and has fallen 95.1% since, to $901 in 2025.

$23,245in general payments, 2019–2025

Across 155 payments — averaging $149.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$18K
  • Abbott$3K
  • Medtronic$370
  • Cvrx, Inc.$308
  • Alnylam Pharmaceuticals Inc.$254
  • Novo Nordisk$251
  • plus $1K from 15 others

What the payments were for

  • Speaking & faculty fees$16,43071%
  • Travel & lodging$9394%
  • Food & beverage$5,87625%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,245 in reported general payments places this provider in the 75th percentile of 28 advanced heart failure and transplant cardiology providers in Tennessee.

See all advanced heart failure and transplant cardiology providers in Tennessee

Medicare billing

Part B allowed, 2024
$122,099
Medicare patients
474
Services billed
1,180

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan1,006$1,133,214
JardianceEmpagliflozin500$550,961
EliquisApixaban356$349,511
FarxigaDapagliflozin Propanediol326$315,272
XareltoRivaroxaban98$87,303
Ambrisentan12$34,200
WegovySemaglutide25$34,194
Metoprolol Succinate890$13,959
Sildenafil Citrate23$9,853
Torsemide268$8,908
Spironolactone994$7,814
Carvedilol757$6,808
Repatha SureclickEvolocumab12$6,628
Isosorbide Dinitrate116$6,281
Ranolazine ErRanolazine49$5,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$18,007$1,133,2141,006 claims
Boehringer IngelheimJardiance$34$550,961500 claims
PfizerEliquis$209$349,511356 claims
AstraZenecaFarxiga$128$315,272326 claims
Novo NordiskWegovy$251$34,19425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 28 advanced heart failure and transplant cardiology providers in Tennessee.

Other advanced heart failure and transplant cardiology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →